Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Aldesleukin + E7 TCR T-cells |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Aldesleukin | Proleukin | IL-2|Interleukin-2|IL2 | Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary). | |
| E7 TCR T-cells | HPV-16 E7 TCR expressing T-cells | E7 TCR T-cells are T-lymphocytes engineered to express a T-cell receptor targeting HPV16 E7, which potentially induce killing of HPV-positive tumor cells (PMID: 33558725). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05639972 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + E7 TCR T-cells | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | Recruiting | USA | 0 |